Lawsuits accuse Fresenius of concealing on GranuFlo, NaturaLyte risks

January 18, 2013 by MassDevice staff

A spate of lawsuits accuse Fresenius Medical (NYSE:FMS) of deliberately concealing potentially fatal problems with a pair of since-recalled products used during dialysis.

The GranuFlo and Naturalyte products were used to lower the acidity of patients' blood during dialysis treatments. At least 15 lawsuits filed since Jan. 1 allege that the dialysates' high concentration of acetone led to abnormally high levels of bicarbonate in the blood, leading to fatal heart problems and strokes, according to court documents.

Sign up to get our free newsletters delivered right to your inbox.

In 1 case, a dialysis patient in Kentucky named Linda Teague allegedly died at age 48 from cardiac arrest after a procedure there.

"Decedent received defendants' defective product during that dialysis treatment and, on or about Jan. 14, 2011, suffered cardiac arrest and died from the injuries she sustained as a result of her exposure to defendants’ defective product," according to the complaint. "Even though defendants knew of the risks for several years, medical providers were unaware that the high levels of bicarbonate in defendants' products heighten the risk of cardiac injury by 6 times. As a result, thousands of patients receiving dialysis treatment were unknowingly overdosed."

An internal Fresenius memo from November 2011 allegedly details the results of a study completed in 2010, "based on data defendants had available for many years," according to the documents.

Permalink